Bicarbonate may not benefit all patients with metabolic acidosis. After SODa-BIC, the question is no longer whether it works, but which patients, might still benefit.
Check out the VA by Daniel Ramirez #NephJC
FIND CKD: The Visual Abstract
Is finerenone ready to move beyond diabetes?
The FIND-CKD phase 3 arrived from the #ERA26 and is the first one to show kidney protection with finerenone in non-diabetic CKD.
The next challenge is no longer whether finerenone belongs in non-diabetic CKD, but how to best combine with the rest of the pillars to maximize protection.
Check out the newest VA created by our intern Raquel Barba
Track: The Visual Abstract
Can rivaroxaban reduce cardiovascular events in advanced CKD?
The TRACK trial compared low-dose rivaroxaban with placebo in patients with stage 4–5 CKD and dialysis-dependent kidney failure at high cardiovascular risk.
Check out the latest VA and review the next #NephJC.
Majesty: The Visual Abstract
Fresh from the #ERA26 Late-Breaking Clinical Trials, the MAJESTY study compared obinutuzumab with tacrolimus and raises important questions about the future of anti-CD20 therapy.
👑 Is deeper B-cell depletion enough to claim the throne?
📖 Check out the latest Visual Abstract by Dr Divya Bajpai
Nondiabetic Kidney Disease: The Visual Abstract
Have we been underestimating NDKD in patients with diabetes? A biopsy-based cohort of 49,075 patients reinforces just how heterogeneous kidney disease can be in DN and highlights the clinical features most strongly associated with NDKD. So, who should we biopsy? When should we suspect NDKD? And how can histology change prognosis?
Join us for this tuesday on the #NephJC discussion
IMPACTS-BP: The Visual Abstract
Can multifaceted strategies improve hypertension control in low-income patients?
Hypertension remains one of the leading cardiovascular risk factors worldwide. However, achieving adequate blood pressure control continues to be a major challenge, especially in low-income populations. The IMPACTS-BP trial has arrived, a study evaluating whether a multifaceted team-based strategy can improve blood pressure control and adherence to antihypertensive therapy.
Check out the VA by Dra Akshaya Jayachandran, and don’t forget to join the live discussion with @NephJC on X and Bluesky
TRPC6 inhibition: The Visual Abstract
For the first time, a podocyte-targeted therapy shows clinical efficacy in FSGS. This week #NephJC covers the phase 2 RCT of BI 764198, an oral TRPC6 inhibitor that lowered proteinuria, preserved eGFR, and was well tolerated. A new era in FSGS? Check out the visual abstract by Divya Bajpai
Can hydralazine trigger ANCA vasculitis?
A large registry cohort was essential to move beyond scattered case reports and finally quantify the true risk of hydralazine‑associated vasculitis. When rare events blur into background noise, only scale can clarify the signal. Can population‑level data sharpen the picture?
Check out Divya Bajpai VA
Hyponatremia Correction: The Visual Abstract
Hyponatremia is one of the most common electrolyte disorders in hospitalized patients and is consistently linked to worse outcomes. Correcting sodium improves the numbers—but does it improve short-term clinical outcomes?
Check out Brian Rifkin VA and the new #NephJC format
REACT: The Visual Abstract
REACT has landed to NephJC.
This time we explore rilparencel, an autologous kidney cell therapy injected directly into the renal cortex to slow kidney function decline in DKD and advanced CKD.
Is this the future of regenerative nephrology?
Take a look at the Visual Abstract Natalia Nombera and join the conversation on #NephJC.
KDIGO 2026 Anemia in CKD: The Visual Abstract
Anemia remains a central challenge in chronic kidney disease, influencing quality of life, cardiovascular risk, and clinical outcomes. The updated KDIGO 2026 guideline provides practical recommendations on iron management, ESAs, HIF-PHIs, and transfusion strategies, emphasizing individualized care and risk–benefit assessment.
Take a quick look at the VA by Michelle Fravel summarizing the key concepts and clinical take-home message
INFINITI: The Visual Abstract
SGLT2i have reshaped cardiorenal care, but kidney transplant recipients have mostly been left out of the story. INFINITI starts to close that gap, testing the safety and physiology of dapagliflozin in stable KTR.
Do #flozins behave the same in transplanted kidneys? Check out the VA by Janany Sabescumar
POTCAST: The Visual Abstract
Can pushing K⁺ to the high-normal range reduce ICD shocks and hospitalizations? POTCAST challenges our fear of potassium.
Check out the VA by Jeyakumar Meyyappan and join the #NephJC conversation
VALIANT: The Visual Abstract
The VALIANT phase 3 RCT shows that proximal C3 inhibition with pegcetacoplan leads to a significantly greater reduction in proteinuria compared with placebo in patients with C3G and primary immune-complex MPGN. This trial builds on prior upstream complement strategies and strengthens the case for disease-targeted therapy in C3G.
Check out the VA Dr. Akshaya Jayachandran and don´t forget to join #NephJC on bluesky.
LIBERATE-D: The Visual Abstract
In patients with dialysis-dependent acute kidney injury, a conservative dialysis strategy was evaluated in the LIBERATE-D trial. Could less be more? Join the discussion in #NephJC, but first, check out the VA created by Sejal Lakhani
PISCES: The Visual Abstract
Curious how n-3 PUFAs may cut serious cardiovascular events in dialysis? 🐟
A big signal, a big dose, and a big discussion ahead — don’t miss this #NephJC!
Check out the VA made by our master Brian Rifkin
ORIGIN-3: The Visual Abstract
KDIGO 2025 IgA guidelines - Visual Abstract
KDIGO 2025 is here. IgAN management is evolving with precision risk tools, new therapies, and a stronger focus on kidney protection.
Check out the visual abstract created by Natalia Nombera
Protein supplementation in CKD: The Visual Abstract
Achieving immune tolerance by chimerism in kidney transplant
Is getting immunosuppression-free a chimera in kidney transplant?
Check out the visual abstract by Bogdan Agavriloaei
